Navigation Links
Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial
Date:9/27/2011

OXFORD, England, September 27, 2011 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive phase II clinical results showing that its ToleroMune® hay fever vaccine substantially improved patients' allergy symptoms compared with those on placebo.  The treatment was extremely well tolerated.  

During the randomised, double-blind, placebo-controlled phase II study conducted in 50 hay fever sufferers in Quebec, Canada, patients received four doses from one of five different treatment regimes over a 12-week period.  Five weeks later, investigators tested the patients' skin and eye responses to grass pollen.  The results show that the treatment reduced allergic symptoms in patients' eyes by up to 30% more than placebo.  In addition, the therapy improved early and late skin reactions by up to 54% and 19% above placebo respectively.  The ToleroMune T-cell vaccine had a similar safety profile to placebo.

Following these results, Circassia has initiated the final phase II trial of its hay fever treatment.  The double-blind, placebo-controlled study is underway in Kingston, Canada in 280 volunteers, and will assess the effectiveness of the ToleroMune T-cell vaccine at improving patients' nasal symptoms and eye responses when exposed to grass pollen in an exposure chamber.  

"Achieving these clinical results is particularly encouraging as hay fever is an extremely common allergy, which can have a major impact on sufferers," said Steve Harris, Circassia's CEO.  "Many current therapies provide short-term symptom relief only, while traditional immunotherapies can require specialist treatment over several years to address the underlying disease.  Circassia's latest results follow earlier successful studies in a range of different allergies.  Our clinical data show that Circassia's T-cell vaccines have the p
'/>"/>

SOURCE Circassia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lactobacillus Beverage Confirmed to Reduce Fever Brought on by Acute Gastroenteritis Caused by Norovirus Infection
2. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
3. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
4. Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
5. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
6. Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
7. Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment
8. The New Face of Personalized Medicine: Targeting Disease Diagnostics and Treatments with Big Data Analytics: October 6, 2011, 1 PM EDT, Webinar
9. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
10. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
11. New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients Functionality and Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... , April 18, 2015 ... CRIS ) will be presenting data at ... American Associate of Cancer Research Annual Meeting (April ...      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , ... proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors program, ...
(Date:4/17/2015)... April 17, 2015 Reed Technology ... in regulatory data management, preparation, and submission to the ... availability of a new Lot Distribution Report (LDR) service ... to remain compliant with the FDA’s new rule on ... FDA to monitor the volume and timing of particular ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
(Date:4/17/2015)...  US-Australian drug discovery company, Novogen, today announced ... with the Feinstein Institute for Medical Research (,Feinstein ... to collaborate with the objective of developing effective ... brings together the drug discovery expertise of Novogen ... Feinstein Institute in neurosciences and oncology. ...
Breaking Biology Technology:Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.511 04/2002 , ... , , , ... , Cell type , Bacteria, gram negative, ...
... , , Multiporator , , , , , , ... , Protocol No. 4308 915.031 12/1999 , , ... , , Cell line , ... Transfection with , Rat-DPP IV (in bidistilled H 2 O), stable transfection, ...
... , , , , , Multiporator , , , , ... Transfection Protocol , Protocol No. 4308 915.023 11/1999 , ... , , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
Cached Biology Technology:Escherichia coli C600 2Escherichia coli C600 3CHO 2BALB/3T3 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... scientific papers by researchers at UC Santa Barbara demonstrate ... to fight cancer and other illnesses. The studies introduce ... use no artificial compounds. Luc Jaeger, associate professor ... is nothing short of a revolution going on in ...
... combination of the biology of marine mammals, mechanical vibrations ... scientists to better understand the potential harmful effects of ... An international team of researchers from UC ... Zoo in Sweden has developed an approach that integrates ...
... 2010 − A York University doctoral student who discovered a ... one morning has completed a study that examines 84 species ... including the one Jason Gibbs found in downtown Toronto − ... or described before. Gibbs, expansive study will help scientists ...
Cached Biology News:Developments in nanobiotechnology at UCSB point to medical applications 2Researchers develop simulation to better understand the effects of sound on marine life 2Researchers develop simulation to better understand the effects of sound on marine life 3York U researcher finds new bee in downtown Toronto 2
... Evaluated for its amino acid acceptor activity using ... Ala, Asp, Gly, Ile, Lys, Pro, Thr, Val, ... Unit Definition: One unit will yield an A ... water (1 cm light path). Physical ...
... use as a carrier in ... Physical form: Solution in 10 ... 1 mM EDTA Preparation Note: ... Concentration: 10 mg/mL ...
... Cleland’s Reagent, Immobilized ... FREEZE. Immobilized form of DTT on polyacrylamide resin ... (Cat. Nos. 233153 , 233156 , ... advantage that no soluble components are added to ...
... White crystalline solid. PACKAGED UNDER INERT ... Contaminants: DNases, proteases, RNases: none detected. ... ≤0.500; (100 mM, 1 cm, 280 nm): ... Soluble in H 2 O. RTECS EK1610000, ...
Biology Products: